What we know and don't know on SARS-CoV-2 and COVID-19

被引:0
|
作者
Silva-Ayarza, Ignacio [1 ,2 ]
Bachelet, Vivienne C. [1 ]
机构
[1] Univ Santiago Chile USACH, Escuela Med, Santiago, Chile
[2] Hosp Barros Luco, Dept Infectol, Santiago, Chile
来源
MEDWAVE | 2021年 / 21卷 / 04期
关键词
SARS-CoV-2; COVID-19; genetic variants; vaccines; treatment; diagnosis; CORONAVIRUS DISEASE 2019; CLINICAL CHARACTERISTICS; HOSPITALIZED-PATIENTS; ANTIBIOTICS; ANTIBODIES; VACCINE; VARIANT; DEATHS;
D O I
10.5867/medwave.2021.04.8198
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus discovered in December 2019 in Wuhan, China, has had an enormous impact on public health worldwide due to its rapid spread and pandemic behavior, challenges in its control and mitigation, and few therapeutic alternatives. In this review, we summarize the pathophysiological mechanisms, clinical presentation, and diagnostic techniques. In addition, the main lineages and the different strategies for disease prevention are reviewed, with emphasis on the development of vaccines and their different platforms. Finally, some of the currently available therapeutic strategies are summarized. Throughout the article, we point out the current knowns and unknowns at the time of writing this article.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Immune Profiling of SARS-CoV-2; What We Know and What We Don't Know
    Zohouri, Mahshid
    Ghods, Atri
    Zamir, Mina Roshan
    Shokri, Fazel
    Ghaderi, Abbas
    [J]. IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2023, 22 (03) : 217 - 232
  • [2] COVID-19 in Children: What We Know and What We Don’t Know?
    Kana Ram Jat
    [J]. Indian Journal of Pediatrics, 2021, 88 : 961 - 961
  • [3] COVID-19 in Children: What We Know and What We Don't Know?
    Jat, Kana Ram
    [J]. INDIAN JOURNAL OF PEDIATRICS, 2021, 88 (10): : 961 - 961
  • [4] SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t
    Paul Lingor
    Antonia F. Demleitner
    Andreas W. Wolff
    Emily Feneberg
    [J]. Journal of Neural Transmission, 2022, 129 : 1155 - 1167
  • [5] Omicron SARS-CoV-2 variant: What we know and what we don't
    Ferre, Valentine Marie
    Peiffer-Smadja, Nathan
    Visseaux, Benoit
    Descamps, Diane
    Ghosn, Jade
    Charpentier, Charlotte
    [J]. ANAESTHESIA CRITICAL CARE & PAIN MEDICINE, 2022, 41 (01)
  • [6] SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't
    Lingor, Paul
    Demleitner, Antonia F.
    Wolff, Andreas W.
    Feneberg, Emily
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2022, 129 (09) : 1155 - 1167
  • [7] Covid-19: What do we know about airborne transmission of SARS-CoV-2?
    Baraniuk, Chris
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2021, 373
  • [8] Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know
    Zelek, Wioleta M.
    Harrison, Richard A.
    [J]. IMMUNOBIOLOGY, 2023, 228 (03)
  • [9] Safer Singing During the SARS-CoV-2 Pandemic: What We Know and What We Don't
    Naunheim, Matthew R.
    Bock, Jonathan
    Doucette, Philip A.
    Hoch, Matthew
    Howell, Ian
    Johns, Michael M.
    Johnson, Aaron M.
    Krishna, Priya
    Meyer, David
    Milstein, Claudio F.
    Nix, John
    Pitman, Michael J.
    Robinson-Martin, Trineice
    Rubin, Adam D.
    Sataloff, Robert T.
    Sims, Herbert Steven
    Titze, Ingo R.
    Carroll, Thomas L.
    [J]. JOURNAL OF VOICE, 2021, 35 (05) : 765 - 771
  • [10] SARS-CoV-2 and COVID-19: How much do we know?
    Wang, M.
    Liao, Z.
    [J]. ACTA VIROLOGICA, 2020, 64 (03) : 288 - 296